Skip to main content
Entheon Biomedical Corp. logo

Entheon Biomedical Corp. — Investor Relations & Filings

Ticker · ENBI ISIN · CA29383X2023 LEI · 894500N2J7IXCCDRWU50 CSE Professional, scientific and technical activities
Open in API
Filings indexed 243 across all filing types
Latest filing 2022-10-31 Regulatory Filings
Country CA Canada
Listing CSE ENBI

About Entheon Biomedical Corp.

https://www.entheonbiomedical.com/

Entheon Biomedical Corp. is a biotechnology research and development company focused on creating therapeutic solutions for addiction and substance use disorders. The company specializes in the development and commercialization of psychedelic medicines, particularly dimethyltryptamine (DMT). Entheon aims to progress psychedelics to therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, and novel compounds tailored for treating these complex conditions.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification form (Form 52-109FV2) signed by the CFO certifying the accuracy and fair presentation of the interim financial report and interim MD&A for the period ended August 31, 2022. It explicitly states it is a certification of interim filings for a venture issuer and does not contain the actual financial data or analysis itself, but rather attests to the filings. The document length is short (3042 characters) and it is primarily an officer certification. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than the interim report itself (IR).
2022-10-31 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate signed by the CEO. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended August 31, 2022. The document is primarily an officer certification letter and does not contain actual financial statements or substantive financial data. It references an interim report but does not include the report itself. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR). The document length is short (3030 characters), consistent with a certification letter rather than a full report.
2022-10-31 English
Interim MD&A - English.pdf
Regulatory Filings
2022-10-31 English
Material change report - English.pdf
Regulatory Filings Classification · 95% confidence The document is titled 'Form 51-102F3 Material Change Report' and details a material change involving the sale of preferred stock in another company. It references National Instrument 51-102, which governs continuous disclosure obligations for Canadian public companies, including material change reports. The content includes a summary and full description of the material change, dates, and contact information for an executive officer. The document is relatively short (3544 characters) and is a formal disclosure of a material event rather than a financial report or earnings release. This fits the definition of a Regulatory Filing (RNS) as it is a regulatory disclosure of a material change event that does not fit into other specific categories like earnings release or capital update.
2022-10-06 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the sale of shares in another company and an update on a clinical study. It does not contain financial statements, detailed financial performance data, or regulatory filings. It is a corporate announcement about a financing transaction (sale of shares) and operational update (clinical study enrollment closure). The document length is about 5,186 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication that this is a full financial report, audit report, or earnings release. The content fits best under Capital/Financing Update (CAP) as it relates to the sale of shares and capital proceeds.
2022-10-05 English
Notice of the meeting and record date - English.pdf
AGM Information Classification · 95% confidence The document is a notice regarding the upcoming Annual General Meeting (AGM) of Entheon Biomedical Corp., specifying the meeting date, record dates for notice and voting, class of securities entitled to vote, and meeting location. It is a formal announcement of meeting logistics rather than the AGM materials or presentations themselves. The document length is short (1542 characters), and it does not contain any financial data or detailed AGM content. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or notices related to the AGM.
2022-09-02 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.